Brief exposure to hyperglycemia activates dendritic cells in vitro and in vivo

Aline M. Thomas; Ying Dong; Nicholas M. Beskid; Andrés J. García; Andrew B. Adams; Julia E. Babensee

doi:10.1002/jcp.29380

Brief exposure to hyperglycemia activates dendritic cells in vitro and in vivo

Aline M. Thomas, Ying Dong, Nicholas M. Beskid, Andrés J. García, Andrew B. Adams, Julia E. Babensee

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Dendritic cells are key players in regulating immunity. These cells both activate and inhibit the immune response depending on their cellular environment. Their response to hyperglycemia, a condition common amongst diabetics wherein glucose is abnormally elevated, remains to be elucidated. In this study, the phenotype and immune response of dendritic cells exposed to hyperglycemia were characterized in vitro and in vivo using the streptozotocin-induced diabetes model. Dendritic cells were shown to be sensitive to hyperglycemia both during and after differentiation from bone marrow precursor cells. Dendritic cell behavior under hyperglycemic conditions was found to vary by phenotype, among which, tolerogenic dendritic cells were particularly sensitive. Expression of the costimulatory molecule CD86 was found to reliably increase when dendritic cells were exposed to hyperglycemia. Additionally, hydrogel-based delivery of the anti-inflammatory molecule interleukin-10 was shown to partially inhibit these effects in vivo.

Original language	English (US)
Pages (from-to)	5120-5129
Number of pages	10
Journal	Journal of cellular physiology
Volume	235
Issue number	6
DOIs	https://doi.org/10.1002/jcp.29380
State	Published - Jun 1 2020
Externally published	Yes

Bibliographical note

Funding Information:
The authors declare they do not have any conflicts of interest to disclose regarding this study. This study was supported by NIH (ACTSI, UL1TR000454; 1 R21 EB019166-01A1), Georgia Partner's Regenerative Medicine (REM) seed grant, and rgw Georgia Immunoengineering Consortium's seed grant. The first author received support from the ILET2 training grant (1 R90 DK098981, 1 T90 DK097787). Authors would like to thank Dr. Allen D. Kirk for consultation regarding immunity in diabetes.

Funding Information:
The authors declare they do not have any conflicts of interest to disclose regarding this study. This study was supported by NIH (ACTSI, UL1TR000454; 1 R21 EB019166‐01A1), Georgia Partner's Regenerative Medicine (REM) seed grant, and rgw Georgia Immunoengineering Consortium's seed grant. The first author received support from the ILET2 training grant (1 R90 DK098981, 1 T90 DK097787). Authors would like to thank Dr. Allen D. Kirk for consultation regarding immunity in diabetes.

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Keywords

dendritic cells
diabetes
hydrogel
hyperglycemia
immunity
interleukin-10

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1002/jcp.29380

Find It

Find It at U of M Libraries

Cite this

@article{514b399a3e5c4d6284908134956166ff,

title = "Brief exposure to hyperglycemia activates dendritic cells in vitro and in vivo",

abstract = "Dendritic cells are key players in regulating immunity. These cells both activate and inhibit the immune response depending on their cellular environment. Their response to hyperglycemia, a condition common amongst diabetics wherein glucose is abnormally elevated, remains to be elucidated. In this study, the phenotype and immune response of dendritic cells exposed to hyperglycemia were characterized in vitro and in vivo using the streptozotocin-induced diabetes model. Dendritic cells were shown to be sensitive to hyperglycemia both during and after differentiation from bone marrow precursor cells. Dendritic cell behavior under hyperglycemic conditions was found to vary by phenotype, among which, tolerogenic dendritic cells were particularly sensitive. Expression of the costimulatory molecule CD86 was found to reliably increase when dendritic cells were exposed to hyperglycemia. Additionally, hydrogel-based delivery of the anti-inflammatory molecule interleukin-10 was shown to partially inhibit these effects in vivo.",

keywords = "dendritic cells, diabetes, hydrogel, hyperglycemia, immunity, interleukin-10",

author = "Thomas, \{Aline M.\} and Ying Dong and Beskid, \{Nicholas M.\} and Garc{\'i}a, \{Andr{\'e}s J.\} and Adams, \{Andrew B.\} and Babensee, \{Julia E.\}",

note = "Funding Information: The authors declare they do not have any conflicts of interest to disclose regarding this study. This study was supported by NIH (ACTSI, UL1TR000454; 1 R21 EB019166-01A1), Georgia Partner's Regenerative Medicine (REM) seed grant, and rgw Georgia Immunoengineering Consortium's seed grant. The first author received support from the ILET2 training grant (1 R90 DK098981, 1 T90 DK097787). Authors would like to thank Dr. Allen D. Kirk for consultation regarding immunity in diabetes. Funding Information: The authors declare they do not have any conflicts of interest to disclose regarding this study. This study was supported by NIH (ACTSI, UL1TR000454; 1 R21 EB019166‐01A1), Georgia Partner's Regenerative Medicine (REM) seed grant, and rgw Georgia Immunoengineering Consortium's seed grant. The first author received support from the ILET2 training grant (1 R90 DK098981, 1 T90 DK097787). Authors would like to thank Dr. Allen D. Kirk for consultation regarding immunity in diabetes. Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = jun,

day = "1",

doi = "10.1002/jcp.29380",

language = "English (US)",

volume = "235",

pages = "5120--5129",

journal = "Journal of cellular physiology",

issn = "0021-9541",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - Brief exposure to hyperglycemia activates dendritic cells in vitro and in vivo

AU - Thomas, Aline M.

AU - Dong, Ying

AU - Beskid, Nicholas M.

AU - García, Andrés J.

AU - Adams, Andrew B.

AU - Babensee, Julia E.

N1 - Funding Information: The authors declare they do not have any conflicts of interest to disclose regarding this study. This study was supported by NIH (ACTSI, UL1TR000454; 1 R21 EB019166-01A1), Georgia Partner's Regenerative Medicine (REM) seed grant, and rgw Georgia Immunoengineering Consortium's seed grant. The first author received support from the ILET2 training grant (1 R90 DK098981, 1 T90 DK097787). Authors would like to thank Dr. Allen D. Kirk for consultation regarding immunity in diabetes. Funding Information: The authors declare they do not have any conflicts of interest to disclose regarding this study. This study was supported by NIH (ACTSI, UL1TR000454; 1 R21 EB019166‐01A1), Georgia Partner's Regenerative Medicine (REM) seed grant, and rgw Georgia Immunoengineering Consortium's seed grant. The first author received support from the ILET2 training grant (1 R90 DK098981, 1 T90 DK097787). Authors would like to thank Dr. Allen D. Kirk for consultation regarding immunity in diabetes. Publisher Copyright: © 2019 Wiley Periodicals, Inc. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Dendritic cells are key players in regulating immunity. These cells both activate and inhibit the immune response depending on their cellular environment. Their response to hyperglycemia, a condition common amongst diabetics wherein glucose is abnormally elevated, remains to be elucidated. In this study, the phenotype and immune response of dendritic cells exposed to hyperglycemia were characterized in vitro and in vivo using the streptozotocin-induced diabetes model. Dendritic cells were shown to be sensitive to hyperglycemia both during and after differentiation from bone marrow precursor cells. Dendritic cell behavior under hyperglycemic conditions was found to vary by phenotype, among which, tolerogenic dendritic cells were particularly sensitive. Expression of the costimulatory molecule CD86 was found to reliably increase when dendritic cells were exposed to hyperglycemia. Additionally, hydrogel-based delivery of the anti-inflammatory molecule interleukin-10 was shown to partially inhibit these effects in vivo.

AB - Dendritic cells are key players in regulating immunity. These cells both activate and inhibit the immune response depending on their cellular environment. Their response to hyperglycemia, a condition common amongst diabetics wherein glucose is abnormally elevated, remains to be elucidated. In this study, the phenotype and immune response of dendritic cells exposed to hyperglycemia were characterized in vitro and in vivo using the streptozotocin-induced diabetes model. Dendritic cells were shown to be sensitive to hyperglycemia both during and after differentiation from bone marrow precursor cells. Dendritic cell behavior under hyperglycemic conditions was found to vary by phenotype, among which, tolerogenic dendritic cells were particularly sensitive. Expression of the costimulatory molecule CD86 was found to reliably increase when dendritic cells were exposed to hyperglycemia. Additionally, hydrogel-based delivery of the anti-inflammatory molecule interleukin-10 was shown to partially inhibit these effects in vivo.

KW - dendritic cells

KW - diabetes

KW - hydrogel

KW - hyperglycemia

KW - immunity

KW - interleukin-10

UR - http://www.scopus.com/inward/record.url?scp=85074595466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074595466&partnerID=8YFLogxK

U2 - 10.1002/jcp.29380

DO - 10.1002/jcp.29380

M3 - Article

C2 - 31674663

AN - SCOPUS:85074595466

SN - 0021-9541

VL - 235

SP - 5120

EP - 5129

JO - Journal of cellular physiology

JF - Journal of cellular physiology

IS - 6

ER -

Brief exposure to hyperglycemia activates dendritic cells in vitro and in vivo

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this